Liraglutide · source year
3 selected, source-linked Liraglutide records carrying a 2012 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
3 selected records.
3 represented types.
3 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01695109 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-09-27, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2012-10517, attributed to FDA and its parent HHS department, on 2012-05-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Victoza,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.
Source: Federal Register via GovInfo ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 20610447 at 2026-07-30T22:15:26.499Z. PubMed recorded a metadata revision date of 2012-02-09 and an Entrez history date of 2010-07-09. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗